ライフサイエンスコーパス: plasma cell dyscrasia

1 changes) is a rare disease associated with a plasma cell dyscrasia.

2 f progression to multiple myeloma or another plasma cell dyscrasia.

3 l for following patients with oligosecretory plasma cell dyscrasia.

4 plantation after relapse of their underlying plasma cell dyscrasia.

5 stemic disorder resulting from an underlying plasma cell dyscrasia.

6 AL patients are untreated for the underlying plasma cell dyscrasia.

7 ents achieving eradication of the underlying plasma cell dyscrasia.

8 eukemia (pPCL), which is the most aggressive plasma cell dyscrasia.

9 nal involvement is a frequent consequence of plasma cell dyscrasias.

10 t a role for nontreatment-related factors in plasma cell dyscrasias.

11 proximal tubule epithelium, particularly in plasma cell dyscrasias.

12 in levels that are seen in patients who have plasma cell dyscrasias.

13 a progressive increase in the progression of plasma cell dyscrasias.

14 t treatment options for patients affected by plasma cell dyscrasias.

15 teria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias.

16 ide insight into the molecular mechanisms of plasma-cell dyscrasias.

17 lly in the setting of comorbidities, such as plasma-cell dyscrasias.

18 nse, defined as no evidence of an underlying plasma cell dyscrasia 1 year after treatment, was achiev

19 eased incidence of monoclonal gammopathy and plasma cell dyscrasias.2,3 The exact mechanism of monocl

20 noglobulin light chains produced by a clonal plasma cell dyscrasia accumulate in tissues and damage v

21 plant and improve outcomes for patients with plasma cell dyscrasia and end-stage kidney disease.

22 thy of undetermined significance (MGUS) is a plasma cell dyscrasia and precursor to multiple myeloma.

23 evolving strategies in kidney transplant for plasma cell dyscrasias and end-stage kidney disease.

24 1 identifies healthy individuals at risk for plasma cell dyscrasias and that dominant inheritance of

25 Plasma cell dyscrasias appear to have a modestly increas

26 the patterns of gene methylated for L/L and plasma cell dyscrasias are different.

27 Plasma cell dyscrasias are frequently encountered malign

28 Plasma cell dyscrasias are frequently encountered malign

29 g those transplanted for Hodgkin lymphoma or plasma cell dyscrasias, but was not observed among those

30 Primary (AL) amyloidosis is a plasma cell dyscrasia characterized by clonal production

31 Its underlying cause is a plasma cell dyscrasia characterized by misfolding of mon

32 Multiple myeloma (MM) is a plasma cell dyscrasia characterized by the presence of m

33 assessable patients with heavily pretreated plasma cell dyscrasias completing one cycle of therapy,

34 patients (60%) at 12 months after treatment, plasma cell dyscrasias could not be detected.

35 influenced by the activity of the underlying plasma cell dyscrasia (dFLC) and nephrotic-range albumin

36 ltivariable Cox regression analysis revealed plasma cell dyscrasia (difference between serum free lig

37 Plasma cell dyscrasias encompass a spectrum from the pre

38 hom BM tests routinely performed to diagnose plasma cell dyscrasia failed to detect lambda+ monoclona

39 loidosis achieve complete remission of their plasma cell dyscrasia, improvement in performance status

40 ell transplantation induces remission of the plasma cell dyscrasia in a substantial proportion of pat

41 Thus, aggressive treatment of the underlying plasma cell dyscrasia in AL amyloidosis can lead to the

42 Light chain-associated amyloidosis (AL) is a plasma cell dyscrasia in which the secreted monoclonal i

43 Patients with plasma cell dyscrasia, including multiple myeloma, AL am

44 Plasma cell dyscrasias, including monoclonal gammopathy

45 opathy of undetermined significance or other plasma cell dyscrasias involving the bone marrow, expres

46 yloidosis and not the result of a monoclonal plasma cell dyscrasia, may be misdiagnosed and lead to i

47 ic bone diseases in malignancies such as the plasma cell dyscrasia multiple myeloma (MM) is not known

48 e useful in differentiating POEMS from other plasma cell dyscrasias, neuropathic processes, and multi

49 POEMS syndrome is a rare plasma cell dyscrasia presenting with polyneuropathy and

50 ding of the pathophysiology and diagnosis of plasma cell dyscrasia related kidney diseases.

51 a continues to expand, but the cause of this plasma cell dyscrasia remains unclear.

52 Primary systemic amyloidosis (AL) is a plasma cell dyscrasia resulting in multisystem failure a

53 In the setting of a plasma cell dyscrasia, significant amounts of free light

54 hey are also largely present in premalignant plasma cell dyscrasia such as monoclonal gammopathy of u

55 rmined significance (MGUS) is a premalignant plasma cell dyscrasia that consistently precedes multipl

56 nsight into the molecular defects underlying plasma cell dyscrasias that may explain their clinical h

57 Advances in plasma cell dyscrasia therapies are improving survival a

58 We analyzed 81 patients with plasma cell dyscrasias using single-cell CNA sequencing.

59 Therapy of the patient's underlying plasma-cell dyscrasia utilizing a daratumumab-based regi

60 If plasma cell dyscrasia was present, histologic confirmati

61 renal cell carcinoma, malignant melanoma, or plasma cell dyscrasia, we related responses to questionn

62 Their plasma cell dyscrasias were evaluated with immunofixatio

63 Well-selected patients with plasma cell dyscrasias whose monoclonal Ig is well contr

64 HF signs and symptoms, diuretic therapy, and plasma cell dyscrasia with evidence of myocardial uptake

65 ring multiple myeloma (SMM) are asymptomatic plasma cell dyscrasias, with a propensity to progress to

66 Four families had two or more members with plasma cell dyscrasias, with or without a single case of